Clinical Cancer Research, Vol 4, Issue 2 317-324, Copyright © 1998 by American Association for Cancer Research

ARTICLES

Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion

JP Eder Jr, JG Supko, T Lynch, M Bryant, E Vosburgh, LN Shulman, G Xu and DW Kufe
Dana-Farber/Partners Cancer Care, Boston, Massachusetts, USA. joseph_eder@dfci.harvard.edu

The camptothecins are a class of potent cytotoxic anticancer agents that interact with the nuclear enzyme topoisomerase I to produce lethal DNA strand cleavages. 9-Amino-20(S)-camptothecin (9AC) was introduced into Phase I clinical trials in dimethylacetamide and polyethylene glycol 400 in a 10 mM phosphoric acid vehicle for i.v. solubility. A lyophilized colloidal dispersion (CD) of 9AC for reconstitution with 20% dextrose in normal saline was developed as an alternative formulation. Patients (ages 25-75 years) with normal liver and kidney function, Eastern Cooperative Oncology Group performance status < or = 2, and up to two prior chemotherapy regimens were treated. The initial infusion rate was 37.5 micrograms/m2/h as a 72-h continuous infusion (2.7 mg/m2 total dose). Patient cohorts were treated with escalating infusion rates until grade 4 hematological or other grade 3 toxicity developed. Pharmacokinetic sampling was performed on all patients, and 9AC lactone concentrations in plasma were determined by a high-performance liquid chromatographic assay. Twenty-five patients received a total of 65 courses of 9AC CD at doses from 2.70 to 4.65 mg/m2. The dose-limiting toxicity was neutropenia, with little nonhematological toxicity. Nonlinear regression analysis of pooled patient data yielded a total plasma clearance of 30.3 +/- 4.5 liters/h/m2, a half-life of 22.5 +/- 8.5 h, a mean residence time of 9.7 +/- 3.5 h, and a steady-state volume of distribution of 325 +/- 145 liters/m2. Although no objective responses were seen, 9 of 25 patients exhibited stable disease for 2-6 months. The plasma pharmacokinetics of 9AC lactone in cancer patients were comparable between the 9AC CD and soluble formulations. The dosing regimen recommended for Phase II trials of the 9AC CD formulation is 54.2 micrograms/m2/h, given as a 72-h continuous i.v. infusion every 3 weeks.

This article has been cited by other articles:

				E. C. Attar, D. J. DeAngelo, J. G. Supko, F. D'Amato, D. Zahrieh, A. Sirulnik, M. Wadleigh, K. K. Ballen, S. McAfee, K. B. Miller, et al. Phase I and Pharmacokinetic Study of Bortezomib in Combination with Idarubicin and Cytarabine in Patients with Acute Myelogenous Leukemia Clin. Cancer Res., March 1, 2008; 14(5): 1446 - 1454. [Abstract] [Full Text] [PDF]

				N. Masubuchi, R. D. May, and R. Atsumi A Predictive Model of Human Myelotoxicity Using Five Camptothecin Derivatives and the In vitro Colony-Forming Unit Granulocyte/Macrophage Assay Clin. Cancer Res., October 1, 2004; 10(19): 6722 - 6731. [Abstract] [Full Text] [PDF]

				J. G. Supko, J. P. Eder Jr., D. P. Ryan, M. V. Seiden, T. J. Lynch, P. C. Amrein, D. W. Kufe, and J. W. Clark Phase I Clinical Trial and Pharmacokinetic Study of the Spicamycin Analog KRN5500 Administered as a 1-Hour Intravenous Infusion for Five Consecutive Days to Patients with Refractory Solid Tumors Clin. Cancer Res., November 1, 2003; 9(14): 5178 - 5186. [Abstract] [Full Text] [PDF]

				H. Q. Xiong, H. T. Tran, T. L. Madden, R. A. Newman, and J. L. Abbruzzese Phase I and Pharmacological Study of Oral 9-Aminocamptothecin Colloidal Dispersion (NSC 603071) in Patients with Advanced Solid Tumors Clin. Cancer Res., June 1, 2003; 9(6): 2066 - 2071. [Abstract] [Full Text] [PDF]

				R. Garcia-Carbonero and J. G. Supko Current Perspectives on the Clinical Experience, Pharmacology, and Continued Development of the Camptothecins Clin. Cancer Res., March 1, 2002; 8(3): 641 - 661. [Abstract] [Full Text] [PDF]

				J. W. SINGER, P. DE VRIES, R. BHATT, J. TULINSKY, P. KLEIN, C. LI, L. MILAS, R. A. LEWIS, and S. WALLACE Conjugation of Camptothecins to Poly-(l-Glutamic Acid) Ann. N.Y. Acad. Sci., December 1, 2000; 922(1): 136 - 150. [Abstract] [Full Text] [PDF]

				F. MUGGIA, L. LIEBES, M. POTMESIL, A. HAMILTON, H. HOCHSTER, G. HORNREICH, J. SORICH, A. DOWNEY, and H. WASSERSTROM Intraperitoneal Topoisomerase-I Inhibitors: Preliminary Findings with 9-Aminocamptothecin Ann. N.Y. Acad. Sci., December 1, 2000; 922(1): 178 - 187. [Abstract] [Full Text] [PDF]

				C. H. TAKIMOTO and R. THOMAS The Clinical Development of 9-Aminocamptothecin Ann. N.Y. Acad. Sci., December 1, 2000; 922(1): 224 - 236. [Abstract] [Full Text] [PDF]

				F. Hochberg, S. A. Grossman, T. Mikkelsen, M. Glantz, J. D. Fisher, S. Piantadosi, and the NABTT CNS Consortium Lack of efficacy of 9-aminocamptothecin in adults with newly diagnosed glioblastoma multiforme and recurrent high-grade astrocytoma Neuro-oncol, January 1, 2000; 2(1): 29 - 33. [Abstract] [PDF]

				A. Sparreboom, M. J. A. de Jonge, C. J. A. Punt, W. J. Loos, K. Nooter, G. Stoter, M. G. Porro, and J. Verweij Prediction of the Systemic Exposure to Oral 9-Amino-20(S)-Camptothecin Using Single-Sample Analysis Drug Metab. Dispos., July 1, 1999; 27(7): 816 - 820. [Abstract] [Full Text]

				M. J.A. de Jonge, C. J.A. Punt, A. H. Gelderblom, W. J. Loos, V. van Beurden, A. S.Th. Planting, M. E.L. van der Burg, L. W.G.M. van Maanen, B. K. Dallaire, J. Verweij, et al. Phase I and Pharmacologic Study of Oral (PEG-1000) 9-Aminocamptothecin in Adult Patients With Solid Tumors J. Clin. Oncol., July 1, 1999; 17(7): 2219 - 2219. [Abstract] [Full Text] [PDF]